About: Simeprevir suppresses SARS-CoV-2 replication and synergizes with remdesivir

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Simeprevir suppresses SARS-CoV-2 replication and synergizes with remdesivir Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Simeprevir suppresses SARS-CoV-2 replication and synergizes with remdesivir
Creator	Hui, David Liang, Po-Huang Chen, Yu Wong, Kam-Bo Dikic, Ivan Zuo, Zhong Chan, Francis Wu, Kuen-Phon Affiliations, † Chan, Anthony Chan, Michael Cheung, Hui, Kenrie Kong, Hong Ng, Ka Shen Aik, Wei Cheung, Yin Kong, Shing, Ka Lo, Ho Shin, Donghyuk Mok, Vincent Chi, John Hei, Hayley Ho, Wang Kaur, Simranjeet Ko, Ho Lai, Hei-Ming Li, 5 Li, Zhongqi Ma, Bowen Ng, Wai-Lung Peter, Man-Hin Shahed Khan, Khadija Wang, Kaidao
Source	BioRxiv
abstract	The recent outbreak of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, is a global threat to human health. By in vitro screening and biochemical characterization, we identified the hepatitis C virus (HCV) protease inhibitor simeprevir as an especially promising repurposable drug for treating COVID-19. We also revealed that simeprevir synergizes with the RNA-dependent RNA polymerase (RdRP) inhibitor remdesivir to suppress the replication of SARS-CoV-2 in vitro. Our results provide preclinical rationale for the combination treatment of simeprevir and remdesivir for the pharmacological management of COVID-19 patients. One Sentence Summary Discovery of simeprevir as a potent suppressor of SARS-CoV-2 viral replication that synergizes remdesivir.
has issue date	2020-05-26(xsd:dateTime)
bibo:doi	10.1101/2020.05.26.116020
has license	biorxiv
sha1sum (hex)	4930270da2df6f716a03b962c62d474439edc321
schema:url	https://doi.org/10.1101/2020.05.26.116020
resource representing a document's title	Simeprevir suppresses SARS-CoV-2 replication and synergizes with remdesivir
schema:publication	bioRxiv
resource representing a document's body	covid:4930270da2df6f716a03b962c62d474439edc321#body_text
is schema:about of	named entity 'SARS-CoV-2' named entity 'SUPPRESSOR' named entity 'simeprevir' named entity 'non-specific' named entity 'microplate reader' named entity 'RNA' named entity 'adverse events' named entity 'HCQ' named entity 'EC50' named entity 'FDA' named entity 'IPTG' named entity 'GenBank' named entity 'SARS-CoV-2' named entity 'cloned' named entity 'infection' named entity 'viral replication cycle' named entity 'glycerol' named entity 'rhodamine' named entity 'emerging infection' named entity 'asymptomatic' named entity 'protease' named entity 'EDTA' named entity '7.5' named entity 'Life Technologies' named entity 'exponential decay' named entity 'remdesivir' named entity 'DMSO' named entity 'rate constant' named entity 'dialysed' named entity 'Lysis buffer' named entity 'bromocriptine' named entity 'infection' named entity 'anti-infectives' named entity 'maltose binding protein' named entity 'protein' named entity 'TCEP' named entity 'β-mercaptoethanol' named entity 'lopinavir/ritonavir' named entity 'viral replication' named entity 'antiviral' named entity 'simeprevir' named entity 'chemically synthesized' named entity 'ribavirin' named entity 'Promega' named entity 'formamide' named entity 'cytotoxicity' named entity 'antivirals' named entity 'remdesivir' named entity 'recombinant' named entity 'EcoRI'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software